Anoat Therapeutics receives cystic fibrosis funding boost
Vital financing will be used to develop novel therapies for condition with high unmet medical need
Read More
Tag: cystic fibrosis
Discovery programme launched by Cystic Fibrosis Syndicate
Aim for participants will be to quickly new antimicrobial therapies to treat chronic respiratory infections
Read More
Vertex receives CHMP positive opinion for Kaftrio in children with cystic fibrosis
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read More
EMA, MHRA to review Vertex’ Kaftrio for children with CF
If approved, up to 2,000 children with CF would be eligible for treatment with the drug
Read More
MHRA approves label extension for Vertex’s Kaftrio combo
Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain
Read More
Triple combo cystic fibrosis therapy Kaftrio scores EU label expansion
Extension means the ‘majority’ of people aged 12 years and older with CF in Europe can now access therapy
Read More
MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic
Murepavadin is being developed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis
Read More
Symkevi/Kalydeco cleared for use in young CF patients
The combination is the first available to treat the underlying cause of CF in this patient group.
Read More
EU nod for Vertex CF therapy Kaftrio
Clearance was based on two global Phase III studies showing statistically significant improvements in lung function
Read More
Vertex and NHS Wales agree on Kaftrio reimbursement
The letter of intent should secure access to the combination for people with cystic fibrosis upon its regulatory approval
Read More
EU expands reach of Vertex’ CF drug Kalydeco
Kalydeco is the only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation
Read More
NHS patients given devices and apps for remote monitoring
The move is part of the NHS drive to give more people connected, personalised care in their own homes
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
